Common painkiller ibuprofen tested as treatment for heart inflammation

NCT ID NCT06686862

Recruiting now Disease control Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial is testing whether a 3-week course of ibuprofen can reduce heart scarring better than standard acetaminophen in people hospitalized with acute myocarditis (heart muscle inflammation). The study will enroll 150 adults with mild cases (normal heart pumping function) and use MRI scans to measure inflammation and scarring over 6 months. If successful, ibuprofen could become a simple, low-cost treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibuprofen
What this could lead to: If it works, this could provide a simple, widely available treatment to reduce heart scarring in acute myocarditis.
What could go wrong: This is a relatively small Phase 3 trial (150 people) and uses an open-label design, which can introduce bias. Ibuprofen may not outperform acetaminophen, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDITIS ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOCARDITIS ACUTE

Contacts and locations

Locations

Hospital Universitario Puerta de Hierro-Majadahonda
RECRUITING

Majadahonda, Madrid, 28222, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.